Dacogen Related Clinical Trials
Phase I/II - Dasatinib and Decitabine [Recruiting]
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus JNJ-56022473 (Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy [Recruiting]
Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients [Active, not recruiting]
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) [Recruiting]
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML [Recruiting]
Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML) [Recruiting]
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) [Completed]
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) [Completed]
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) [Recruiting]
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Completed]
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) [Completed]
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) [Completed]
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [Recruiting]
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer [Completed]
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma [Terminated]
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) [Recruiting]
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia [Completed]
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [Completed]
Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia [Recruiting]
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) [Completed]
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma [Completed]
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) [Recruiting]
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) [Recruiting]
A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [Active, not recruiting]
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia [Recruiting]
Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients [Completed]
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia [Completed]
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia [Recruiting]
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk [Recruiting]
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome [Completed]
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 [Recruiting]
Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia [Completed]
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome [Completed]
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Recruiting]
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant [Active, not recruiting]
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) [Recruiting]
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Completed]
Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia [Active, not recruiting]
Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment [Completed]
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Completed]
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) [Completed]
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients [Terminated]
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Terminated]
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes [Completed]
Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies [Recruiting]
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia [Recruiting]
Re-expression of ER in Triple Negative Breast Cancers [Terminated]
Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age > 60 [Recruiting]
Low-dose Decitabine for the Treatment of Refractory Immune Thrombocytopenia [Recruiting]
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Recruiting]
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Completed]
A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome [Completed]
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia [Active, not recruiting]
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) [Active, not recruiting]
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia [Completed]
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [Active, not recruiting]
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia [Completed]
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia [Completed]
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Completed]
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [Completed]
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML [Recruiting]
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases [Completed]
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Active, not recruiting]
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome [Completed]
Phase I, Dose Escalation Study of Decitabine [Recruiting]
Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease [Recruiting]
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure [Terminated]
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) [Completed]
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) [Completed]
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes [Completed]
Trial of Decitabine in Patients With Acute Myeloid Leukemia [Completed]
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors [Terminated]
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes [Completed]
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure [Recruiting]
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib [Recruiting]
A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome [Completed]
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat [Recruiting]
Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas [Recruiting]
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 [Completed]
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm [Recruiting]
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [Terminated]
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer [Completed]
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients [Recruiting]
A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia [Recruiting]
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome [Completed]
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) [Not yet recruiting]
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma [Completed]
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS. [Terminated]
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
|